Sandoz Breaks Ground on $440M Slovenia Biosimilars Facility

Sandoz, a global leader in generic and biosimilar medicines, has commenced construction of a $440 million state-of-the-art biosimilars production facility in Brnik, Slovenia, which is part of its broader $1.1 billion investment plan in the country through 2029. The new plant will focus on sterile injectable biosimilars, handling preparation, filling, assembly, and packaging, and will complement existing investments including a drug substance production center in Lendava and a development center in Ljubljana. This expansion supports Sandoz's strategy to build an integrated European biosimilar hub and capitalize on the market opportunity presented by $222 billion in biosimilar patent expiries over the next decade. CEO Richard Saynor emphasized the importance of biosimilars as the fastest-growing segment of the company's pipeline and highlighted Slovenia's strategic value due to its skilled workforce, central location, and strong infrastructure. The facility is expected to enhance Sandoz's manufacturing capacity to meet growing patient demand and solidify its position as Slovenia’s largest direct foreign investor. The project aligns with Sandoz's commitment to expanding patient access to affordable biologic medicines and strengthening its global biosimilars market leadership.